| CAS NO. |
Products Name |
|
|
| 1231220-79-3 |
LY2828360 |
more... |
| LY2828360 is a slowly acting but efficacious G protein-biased cannabinoid (CB2) agonist, inhibiting cAMP accumulation and activating ERK1/2 signaling. |
|
| 1001600-56-1 |
BV6 |
more... |
| BV6 is an antagonist of cIAP1 and XIAP, members of the inhibitors of apoptosis (IAP) family. |
|
| 209860-87-7 |
Tafluprost |
more... |
| Tafluprost(AFP-168) is an anti-glaucoma prostaglandin (PG) analog. Target:Others Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic patterns [1]. Tafluprost with reduced BAK has potential as a superior antiglaucoma drug, not only for its IOP-lowering effect, but also for its good corneal safety profile [2]. Tafluprost single-use vials treatment was effective in reducing IOP over the 3 years of this study, but visual field performance worsened by 10.3%-13.8% in patients with normal-tension glaucoma. Safety was satisfactory |
|
|
|
|
|
|
|
| 905579-51-3 |
MLN4924 |
more... |
| Pevonedistat (MLN4924) is a potent and selective NEDD8-activating enzyme (NAE) inhibitor with an IC50 of 4.7 nM. |
|
| 835598-94-2 |
GLX351322 |
more... |
| GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4), and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC50 of 5 μM. |
|
|
|
| 2172879-52-4 |
LIT-927 |
more... |
| LIT-927 is a locally and orally active CXCL12 neutraligand with anti-inflammatory effect, with a Ki of 267 nM for CXCL12 binding to its specific receptor CXCR4 |
|
| 1821143-79-6 |
DMU2105 |
more... |
| DMU2105 is a potent and specific CYP1B1 inhibitor, with IC50s of 10 nM and 742 nM for CYP1B1 and CYP1A1, respectively. |
|
All Products
